key: cord-0022894-sj7jyqac
authors: See, Kay Choong
title: Glycemic targets in critically ill adults: A mini-review
date: 2021-10-15
journal: World J Diabetes
DOI: 10.4239/wjd.v12.i10.1719
sha: c24901e450dd250c4a7196b756bec520b33be1e0
doc_id: 22894
cord_uid: sj7jyqac

Illness-induced hyperglycemia impairs neutrophil function, increases pro-inflammatory cytokines, inhibits fibrinolysis, and promotes cellular damage. In turn, these mechanisms lead to pneumonia and surgical site infections, prolonged mechanical ventilation, prolonged hospitalization, and increased mortality. For optimal glucose control, blood glucose measurements need to be done accurately, frequently, and promptly. When choosing glycemic targets, one should keep the glycemic variability < 4 mmol/L and avoid targeting a lower limit of blood glucose < 4.4 mmol/L. The upper limit of blood glucose should be set according to casemix and the quality of glucose control. A lower glycemic target range (i.e., blood glucose 4.5-7.8 mmol/L) would be favored for patients without diabetes mellitus, with traumatic brain injury, or who are at risk of surgical site infection. To avoid harm from hypoglycemia, strict adherence to glycemic control protocols and timely glucose measurements are required. In contrast, a higher glycemic target range (i.e., blood glucose 7.8-10 mmol/L) would be favored as a default choice for medical-surgical patients and patients with diabetes mellitus. These targets may be modified if technical advances for blood glucose measurement and control can be achieved.

Illness-induced hyperglycemia can be a double-edged sword. On the one hand, it may be an adaptive response to provide extra metabolic substrate to organs like the brain and to blood cells [1] . On the other hand, hyperglycemia impairs neutrophil function and innate immunity, increases pro-inflammatory cytokines and oxidative stress[2,3], inhibits fibrinolysis [4] , and promotes cellular damage [1] . In addition, hyperglycemia in brain-injured patients can lead to microcirculatory damage, blood-brain barrier disruption, and cellular swelling [5] . These pathological derangements potentially lead to complications such as pneumonia and surgical site infections, prolonged mechanical ventilation, increased intensive care unit (ICU) and hospital lengths of stay, and increased mortality.

Unlike hyperglycemia, hypoglycemia is always harmful. For example, hypoglycemia was independently associated with respiratory complications and prolonged ICU and hospital lengths of stay after cardiac surgery [6] . These adverse events may be mediated by hypoglycemia-related neuronal damage and cardiac arrhythmia [7] . Apart from the clear need to avoid blood glucose extremes, there is also a need to avoid excessive blood glucose fluctuations [8] , which can be measured in various ways ( Table 1 ). The simplest measure of blood glucose fluctuation is glycemic variability, which is the difference between the maximum and minimum blood glucose measured over a defined time interval. At the cellular level, glycemic variability has been associated with oxidative stress, endothelial dysfunction, and apoptosis [7] . Clinically, glycemic variability has been linked to increased ICU and hospital mortality[9,10].

Blood glucose measurements need to be done accurately, frequently, and promptly [11] . Ideally, blood glucose measurements should be done continuously, though continuous glucose monitoring (CGM) for critically ill patients may not be accurate enough, with wide limits of agreement despite small mean bias [12] . CGM appears unreliable when using minimally-invasive subcutaneous devices that assay interstitial glucose measurements[13-15], and does not seem to improve glucose control [16] . Although invasive (intravascular) CGM devices may have an acceptable accuracy, some drawbacks include vascular and infectious complications (thrombosis, catheter occlusion, biofilm formation, or intravascular catheter-related infection) [17, 18] .

Accuracy and variation of glucose measurement methods influence the feasibility and adherence to glycemic targets [19] . In the real world, a variety of blood samples (arterial, venous, and capillary) are assayed intermittently, using both point-of-care and laboratory methods [20, 21] , and managed using various protocols. Nonetheless, despite such variation, clinical utility of current glucose measurement systems seems adequate, with little evidence of over or under-treatment [22] . Additionally, to achieve optimal clinical outcomes, blood glucose should be lowered if it were to rise too high, blood glucose should not be allowed to dip too low, and blood glucose variability should be constrained.

To determine clinically optimal glycemic targets for critically ill adult patients, the key questions would therefore be as follows: (1) What should the hyperglycemic threshold be; (2) What should the hypoglycemic threshold be; and (3) How far apart should these thresholds be? This review aims to integrate empirical evidence to answer these questions, and to suggest practical recommendations for choosing glycemic targets. 

Several trials are inconclusive with respect to intensive (lower) vs conventional (higher) glycemic targets, which may be due to insufficient separation of achieved glucose levels between the intervention and control groups [23] [24] [25] . Another reason could be that the impact of glucose control was modified by the main diagnosis (i.e., casemix). In terms of the hyperglycemic threshold, the blood glucose level beyond which clinical complications occur seems to differ by casemix ( The NICE-SUGAR trial showed that undifferentiated medical-surgical ICU patients had decreased 90-d mortality and incident hypoglycemia when the upper limit of blood glucose was set at 10 mmol/L rather than 6.1 mmol/L[31]. Patients who suffered non-TBI-specific injury [32] or who had post-cardiac arrest[33] also experienced better neurological recovery if blood glucose could be kept below 10 mmol/L. Patients with prior DM were able to tolerate a higher mean blood glucose level (i.e., blood glucose level > 10 mmol/L) without excess complications during critical illness, although these patients benefited from lowering blood glucose below 7.8 mmol/L after coronary artery bypass surgery [34] . Chronic hyperglycemia may have compensatory mechanisms in place that provide protection from acute hyperglycemiarelated cellular damage[2]. The upper limit of safety in patients with DM appears to be a blood glucose level of 14 mmol/L [35] .

In contrast to the risk of hyperglycemia differing by casemix, the risks of hypoglycemia appear to affect a broad range of patients similarly. Severe hypoglycemia (< 2.2 mmol/L), moderate hypoglycemia (< 3.3 mmol/L), and even mild hypoglycemia (<4 mmol/L) have been associated with ICU and hospital mortality[36-39]. Targeting lower blood glucose levels resulted in higher rates of severe hypoglycemia [40, 41] , and no clinical trial has targeted a lower limit of blood glucose < 4.4 mmol/L. The NICE-SUGAR trial demonstrated that the risk of hypoglycemia can be mitigated by avoiding targeting blood glucose below 6.1 mmol/L[31]. Nonetheless, if intensive glucose monitoring and management resources are available, and if glycemic control protocols and timely glucose measurements can be strictly adhered to, the Leuven studies demonstrated advantages of targeting blood glucose below 6.1 mmol/L, with surgical patients deriving clearer survival benefit and morbidity reduction compared to medical patients[23,42].

In a multicenter observational study, Egi et al [43] first showed that ICU non-survivors had a wider spread of glucose values compared to ICU survivors. Specifically, the standard deviation of blood glucose values was 2.3 mmol/L in non-survivors compared to 1.3 mmol/L in survivors. The association between spread of blood glucose with hospital mortality persisted after controlling for confounders (hospital site, surgical patients, neurologic diseases, mechanical ventilation, acute physiological and chronic health evaluation II score, age, mean blood glucose level, maximum blood glucose level, and admission blood glucose level). Subsequently, other observational studies have demonstrated that the difference between maximum and minimum blood glucose levels (i.e., glucose variability) should not exceed 4-6 mmol/L, regardless of casemix[10,44,45] (Table 3) . In other words, glycemic target ranges should ideally be < 4 mmol/L in width. Such a narrow range seems to be achievable, given that both single-center and multi-center randomized trials using a variety of protocols have successfully constrained glucose levels within standard deviations of < 2 mmol/L[23,31,42,46].

To minimize patient harm, empirical evidence suggests that when choosing glycemic targets, one should keep the glycemic variability < 4 mmol/L and avoid targeting a lower limit of blood glucose < 4.4 mmol/L. The upper limit of blood glucose should then be set according to casemix and the quality of glucose control.

A lower glycemic target range (i.e., blood glucose 4.5-7.8 mmol/L) would be favored for patients without DM, with TBI, or who are postoperative and at risk of surgical site infection. Requirements for targeting a lower range and avoiding harm from hypoglycemia would be availability of intensive glucose monitoring and management, strict adherence to glycemic control protocols, and strict adherence to timely glucose measurements (Table 4) .

In contrast, a higher glycemic target range (i.e., blood glucose 7.8-10 mmol/L) would be favored as a default choice for medical-surgical patients and patients with DM. Additionally, a higher range would be favored if conditions to avoid hypoglycemia cannot be strictly met, i.e., lack of intensive glucose monitoring and management, less than strict adherence to glycemic control protocols, and less than strict adherence to timely glucose measurements. October 15, 2021

Volume 12 Issue 10 This review's recommendations are in line with current guidelines (Table 5) Other guidelines have made less definite recommendations. For surgical patients, the World Health Organization recommends glucose control, though no target range was defined [50] . For patients with TBI, the Brain Trauma Foundation does not mention glycemic control [51] . The findings and recommendations from this review can therefore help fill any gaps in these latter guidelines.

To increase the safety of lower glycemic targets, technical advances for blood glucose measurement and control would help. Autocorrecting point-of-care glucose measurement devices can adjust for interfering substances (e.g., ascorbic acid and nonglucose sugars) and abnormal hematocrit in critically ill patients[52], enabling these devices to become as accurate as central laboratory plasma glucose measurements. Monte Carlo simulation suggests that glycemic control in critically ill patients is optimal with a blood glucose measurement interval no longer than 1 h, with incremental benefit using shorter measurement intervals of 15 min [53] . This means that devices that can continuously assay blood glucose would be needed. Optimization of glucose control protocols with respect to the following aspects may also be investigated: (1) Addition of bolus insulin "mid-protocol" during an insulin infusion to reduce peak insulin rates for insulin-resistant patients[63]; (2) transition of insulin administration route from intravenous to subcutaneous [64] , and (3) use of DMspecific enteral formula for both DM and non-DM patients [65] [66] [67] .

Given the influence of casemix on the optimal glycemic target range, further work may be done to personalize recommendations for various conditions [68] . For patients with DM, it remains unclear if the upper limit of blood glucose can be safely pushed beyond 10 mmol/L [69] , given the risk of ketoacidosis or ketonemia [70] . To address this uncertainty, the LUCID trial will investigate if liberal blood glucose (target 10.0-14.0 mmol/L) will result in less incident hypoglycemia compared to usual care (target 6.0-10.0 mmol/L), while maintaining good clinical outcomes [71] .

When choosing glycemic targets, one should keep the glycemic variability < 4 mmol/L and avoid targeting a lower limit of blood glucose < 4.4 mmol/L. The upper limit of blood glucose should be set according to casemix and the quality of glucose control. A lower glycemic target range (i.e., blood glucose 4.5-7.8 mmol/L) would be favored for patients without diabetes mellitus, with traumatic brain injury, or who are at risk of surgical site infection. To avoid harm from hypoglycemia, strict adherence to glycemic control protocols and timely glucose measurements are required. In contrast, a higher glycemic target range (i.e., blood glucose 7.8-10 mmol/L) would be favored as a default choice for medical-surgical patients and patients with diabetes mellitus. These targets may be modified if technical advances for blood glucose measurement and control can be achieved. 

Tight glycaemic control by an automated algorithm with time-variant sampling in medical ICU patients

A computerized insulin infusion titration protocol improves glucose control with less hypoglycemia compared to a manual titration protocol in a trauma intensive care unit

Minimization of Hypoglycemia as an Adverse Event During Insulin Infusion: Further Refinement of the Yale Protocol

Conversion from continuous insulin infusions to subcutaneous insulin in critically ill patients

Diabetes-specific enteral nutrition formula in hyperglycemic, mechanically ventilated, critically ill patients: a prospective, open-label, blind-randomized, multicenter study

Glycemic Effects of a Low-Carbohydrate Enteral Formula Compared With an Enteral Formula of Standard Composition in Critically Ill Patients: An Open-Label Randomized Controlled Clinical Trial

The effect of a low carbohydrate formula on glycaemia in critically ill enterally-fed adult patients with hyperglycaemia: A blinded randomised feasibility trial

Associations between blood glucose level and outcomes of adult in-hospital cardiac arrest: a retrospective cohort study

Dysglycaemia in the critically ill and the interaction of chronic and acute glycaemia with mortality

Prevalence of ketosis, ketonuria, and ketoacidosis during liberal glycemic control in critically ill patients with diabetes: an observational study

LUCID Study Investigators; ANZICS Clinical Trials Group. Study protocol and statistical analysis plan for the Liberal Glucose Control in Critically Ill Patients with Pre-existing Type 2 Diabetes (LUCID) trial

Intensive insulin therapy is associated with reduced infectious complications in burn patients

Lower Glucose Target Is Associated With Improved 30-Day Mortality in Cardiac and Cardiothoracic Patients

Liberal Glucose Control in ICU Patients With Diabetes: A Beforeand-After Study

Hospital-acquired complications in intensive care unit patients with diabetes: A before-and-after study of a conventional vs liberal glucose control protocol

Moderate glucose control is associated with increased mortality compared with tight glucose control in critically ill patients without diabetes

Failure to achieve glycemic control despite intensive insulin therapy in a medical ICU: incidence and influence on ICU mortality

Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial

A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study

Mean glucose during ICU admission is related to mortality by a U-shaped curve in surgical and medical patients: a retrospective cohort study

Tight computerized vs conventional glucose control in the ICU: a randomized controlled trial

Glucose control and mortality in critically ill patients

Intensive insulin therapy in mixed medical/surgical intensive care units: benefit vs harm

What is the optimal blood glucose target in critically ill patients?

Time in blood glucose range 70 to 140 mg/dL >80% is strongly associated with increased survival in non-diabetic critically ill adults

Percentage of Time in Range 70 to 139 mg/dL Is Associated With Reduced Mortality Among Critically Ill Patients Receiving IV Insulin Infusion

Relative Hyperglycemia Is an Independent Determinant of In-Hospital Mortality in Patients With Critical Illness

Proportion of time spent in blood glucose range 70 to 140 mg/dL is associated with increased survival in patients admitted to ICU after cardiac arrest: A multicenter observational study

Tight perioperative glucose control is associated with a reduction in renal impairment and renal failure in non-diabetic cardiac surgical patients

Intensive vs intermediate glucose control in surgical intensive care unit patients

Effects of intensive glycemic control on outcomes of cardiac surgery

Intensive vs conventional glucose control in critically ill patients with traumatic brain injury: long-term follow-up of a subgroup of patients from the NICE-SUGAR study

Glucose control and mortality in patients with severe traumatic brain injury

Poor glycemic control is associated with increased mortality in critically ill trauma patients

The association between long-term glycaemic control, glycaemic gap and neurological outcome of inhospital cardiac arrest in diabetics: A retrospective cohort study